GlassScriptPhysician profile
John W Hale
NPI 1104806413
$10,431.16
in general payments reported to CMS, 2019-2025
32 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $859 · 2021: $1,418 · 2022: $1,624 · 2023: $1,768 · 2024: $1,504 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,936 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,935.74 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,397.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,246.60 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $919.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $848.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $798.96 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.20 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $662.95 | 2019-2022 | |
| Pfizer INC. | $547.21 | 2019-2025 | |
| Abbvie INC. | $435.83 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $275.69 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbott Laboratories | $186.38 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $152.01 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $151.14 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $132.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $113.31 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $93.80 | 2020-2025 | Trelegy Ellipta |
| Eisai INC. | $90.08 | 2020-2021 | |
| Dexcom, INC. | $84.29 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $67.32 | 2020-2025 | Austedo Xr |
| Daiichi Sankyo INC. | $64.63 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $57.56 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $55.35 | 2019 | |
| Exact Sciences Corporation | $49.68 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $44.62 | 2022 | |
| Esperion Therapeutics, INC. | $42.84 | 2025 | Nexletol |
| Amarin Pharma, INC. | $39.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $25.13 | 2023 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $17.85 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2025 | Caplyta |
| Celgene Corporation | $12.80 | 2019 | |
| Sanofi Pasteur INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.